Arcadia Biosciences (NASDAQ:RKDA) Coverage Initiated by Analysts at StockNews.com

StockNews.com assumed coverage on shares of Arcadia Biosciences (NASDAQ:RKDAFree Report) in a report published on Wednesday. The firm issued a sell rating on the basic materials company’s stock.

Separately, HC Wainwright reiterated a “buy” rating and set a $6.00 target price on shares of Arcadia Biosciences in a report on Wednesday, August 21st.

View Our Latest Analysis on Arcadia Biosciences

Arcadia Biosciences Trading Up 2.6 %

Shares of NASDAQ RKDA opened at $4.36 on Wednesday. The stock has a fifty day simple moving average of $3.09 and a 200-day simple moving average of $2.86. Arcadia Biosciences has a twelve month low of $1.85 and a twelve month high of $5.34. The stock has a market capitalization of $5.94 million, a PE ratio of -0.84 and a beta of 1.34.

Arcadia Biosciences (NASDAQ:RKDAGet Free Report) last released its earnings results on Tuesday, August 13th. The basic materials company reported $0.78 earnings per share for the quarter, missing the consensus estimate of $1.27 by ($0.49). The firm had revenue of $1.31 million during the quarter, compared to analyst estimates of $0.95 million. Arcadia Biosciences had a negative net margin of 127.29% and a negative return on equity of 57.51%. During the same period in the prior year, the firm earned ($2.64) earnings per share. On average, equities analysts predict that Arcadia Biosciences will post -1.7 earnings per share for the current year.

About Arcadia Biosciences

(Get Free Report)

Arcadia Biosciences, Inc produces and markets plant-based food and beverage products in the United States. The company develops crop improvements primarily in wheat to enhance farm economics by improving the performance of crops in the field, as well as their value as food ingredients. Its food, beverage, and body case products include GoodWheat, Zola coconut water, ProVault topical pain relief, and SoulSpring.

Featured Articles

Receive News & Ratings for Arcadia Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arcadia Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.